NASDAQ:BTAI - BioXcel Therapeutics Stock Price, Forecast & News

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its quarterly earnings results on Thursday, November, 14th. The company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $0.02. View BioXcel Therapeutics' Earnings History.

BioXcel Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for BioXcel Therapeutics.

4 equities research analysts have issued 12-month price targets for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $30.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $26.75 in the next twelve months. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for BioXcel Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.

Press coverage about BTAI stock has trended somewhat positive on Wednesday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioXcel Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for BioXcel Therapeutics.

BioXcel Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 457,000 shares, a drop of 23.2% from the January 15th total of 595,200 shares. Based on an average daily trading volume, of 233,400 shares, the days-to-cover ratio is presently 2.0 days. Approximately 5.6% of the company's stock are short sold. View BioXcel Therapeutics' Current Options Chain.

Some companies that are related to BioXcel Therapeutics include Biohaven Pharmaceutical (BHVN), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Aurinia Pharmaceuticals (AUPH), Forty Seven (FTSV), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Epizyme (EPZM), Pacira Biosciences (PCRX), Karuna Therapeutics (KRTX), Xencor (XNCR), Eidos Therapeutics (EIDX), Turning Point Therapeutics (TPTX) and Ironwood Pharmaceuticals (IRWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include Alibaba Group (BABA), Tesla (TSLA), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Canopy Growth (CGC), Sangamo Therapeutics (SGMO), IQIYI (IQ), Micron Technology (MU), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Artemis Investment Management LLP (5.95%), Point72 Asset Management L.P. (1.41%), Ikarian Capital LLC (0.88%), State Street Corp (0.55%), UBS Group AG (0.52%) and Geode Capital Management LLC (0.44%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Institutional Ownership Trends for BioXcel Therapeutics.

BTAI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Renaissance Technologies LLC and Bank of America Corp DE. View Insider Buying and Selling for BioXcel Therapeutics.

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Banco Bilbao Vizcaya Argentaria S.A., Point72 Asset Management L.P., Oxford Asset Management LLP, Geode Capital Management LLC, State Street Corp, Creative Planning and UBS Group AG. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Insider Buying and Selling for BioXcel Therapeutics.

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BTAI stock can currently be purchased for approximately $32.48.

BioXcel Therapeutics has a market capitalization of $587.47 million. The company earns $-19,270,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.View Additional Information About BioXcel Therapeutics.

The official website for BioXcel Therapeutics is http://www.bioxceltherapeutics.com/.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]